A better understanding of the placental factors driving the pregnancy-related decline in insulin sensitivity could lead to new therapeutic approaches to hyperglycemia, early identification of those at risk of developing GDM and recognition of those most likely to have GDM-related pregnancy complications. This evidence concerns the gene INS and gestational diabetes.